Support The Moscow Times!

Novartis Unit Considers Russian Factory

Sandoz, the world's second largest generic medicine company, is still mulling its options for owning a plant in Russia, company chief Jeff George said in an interview.

“Russia, being one of our top markets, is a very important, strategic market for investment in the future,” he said in an interview at the end of last month. “We are currently evaluating what is the right way to invest.”

Sandoz and Novartis, its parent company, are still seeking guidance from government officials as they look to develop more concrete plans, he said.

Switzerland-based Novartis, which is Russia’s biggest pharmaceutical company in terms of sales, wanted to make a decision within two or three years, the company’s chief Daniel Vasella said in January. It first announced the idea to buy or build a drug-making plant in Russia in 2008.

… we have a small favor to ask.

As you may have heard, The Moscow Times, an independent news source for over 30 years, has been unjustly branded as a "foreign agent" by the Russian government. This blatant attempt to silence our voice is a direct assault on the integrity of journalism and the values we hold dear.

We, the journalists of The Moscow Times, refuse to be silenced. Our commitment to providing accurate and unbiased reporting on Russia remains unshaken. But we need your help to continue our critical mission.

Your support, no matter how small, makes a world of difference. If you can, please support us monthly starting from just 2. It's quick to set up, and you can be confident that you're making a significant impact every month by supporting open, independent journalism. Thank you.

Continue

Read more